Hematology Tissue Bank

The Hematology Tissue Bank Shared Resource (HTBSR) is CAP Accredited.

Director: Lapo Alinari, MD, PhD
Senior Faculty Advisor: Robert Baiocchi, MD, PhD
Assistant Director: Christopher Manring, MBA

Place an Order in eRAMP

Sample Request Form

These samples are available to investigators at The Ohio State University Wexner Medical Center and to outside collaborators who study the cellular and molecular properties of these diseases. The ability to examine tumor cells from patients is an essential part of determining the causes of cancer and developing new and effective treatments.

A National Cancer Institute (NCI)-sponsored biorepository, the HTBSR has more than 85,000 vials of cryopreserved viable cells and 17,000 vials of matched frozen plasma and/or serum samples from more than 9,000 patients.

Key program objectives

The Specific Aims of the HTBSR are to:

• Aim 1: Consent subjects and procure samples from patients with hematologic diseases.
• Aim 2: Uniformly process, characterize and store biospecimens using state-of-the art procedures.
• Aim 3: Provide de-identified biospecimens with associated clinical, pathological and genomic data to OSUCCC – James researchers and to outside institutions so that they can correlate findings from patient samples with clinical or population-based outcomes. 

Committed to furthering translational research efforts for OSUCCC – James members and the research community, the HTBSR provides investigators with training and technical support as well as procurement, processing, storage, retrieval and distribution of clinical research materials from patients with any hematologic disease.

Cross-institutional work

The HTBSR is a central processing and storage laboratory for several multi-site clinical trials for which the principal investigator is an OSUCCC member. Certain trials may be a collaboration of hematologic disease and other cancers to determine efficacy and predictability. These include:

OSU 22091: To evaluate the length of time until development of a myeloid neoplasm (i.e. MDS, MPN, CMML, or AML) in high-risk CCUS patients receiving canakinumab as therapeutic intervention compared to the control arm. (U. Borate, PI)

OSU 21025: To assess the safety and tolerability and identify the maximum tolerated dose (MTD) of CRI-400945 administered orally in patients with acute myeloid leukemia (AML), Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML). (A. Mims, PI)

OSU 21071: To estimate the PFS of patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) treated with chemo-immunotherapy followed by maintenance ceralasertib plus durvalumab. (A. Alahmadi, PI).

OSU 21170: To determine the safety of the treatment of relapsed or refractory B cell lymphomas, relapsed/refractory chronic lymphocytic leukemia and relapsed/refractory acute lymphoblastic leukemia with chimeric antigen receptor T cells (CAR T) targeting CD19/CD20/CD22 and to find the recommended phase II dose for this cellular therapy. (S. Vasu, PI).

OSU 22140: To evaluate the anti-tumor activity of Tafasitamab and ICE as salvage therapy for Relapsed/Refractory Large B-Cell Lymphoma as assessed by the cumulative complete response rate after completion of 2 or 4 cycles of study treatment. (D. Bond, PI).